{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:27:05Z","timestamp":1791019625444,"version":"4.1.0"},"reference-count":65,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2010,10,11]],"date-time":"2010-10-11T00:00:00Z","timestamp":1286755200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0013253","type":"journal-article","created":{"date-parts":[[2010,10,11]],"date-time":"2010-10-11T19:39:28Z","timestamp":1286825968000},"page":"e13253","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":50,"title":["Inhibition of Toxic Shock by Human Monoclonal Antibodies against Staphylococcal Enterotoxin B"],"prefix":"10.1371","volume":"5","author":[{"given":"Eileen A.","family":"Larkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley G.","family":"Stiles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Ulrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2010,10,11]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"S350","DOI":"10.1086\/533591","article-title":"Pathogenesis of methicillin-resistant <italic>Staphylococcus aureus<\/italic> infection.","volume":"46","author":"RJ Gordon","year":"2008","journal-title":"Clin Infect Dis"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"S344","DOI":"10.1086\/533590","article-title":"Epidemiology of methicillin-resistant <italic>Staphylococcus aureus<\/italic>.","volume":"46","author":"HW Boucher","year":"2008","journal-title":"Clin Infect Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3201\/eid1302.060781","article-title":"Community-associated methicillin-resistant <italic>Staphylococcus aureus<\/italic> isolates causing healthcare-associated infections.","volume":"13","author":"CL Maree","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1001\/jama.298.15.1763","article-title":"Invasive methicillin-resistant <italic>Staphylococcus aureus<\/italic> infections in the United States.","volume":"298","author":"RM Klevens","year":"2007","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1586\/14787210.6.5.751","article-title":"Clinical and economic burden of antimicrobial resistance.","volume":"6","author":"LL Maragakis","year":"2008","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1185\/03007990802365169","article-title":"Costs of skin and skin structure infections due to <italic>Staphylococcus aureus<\/italic>: an analysis of managed-care claims.","volume":"24","author":"JP Marton","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1128\/IAI.45.1.281-285.1984","article-title":"Monoclonal antibodies to staphylococcal enterotoxins B and C: cross-reactivity and localization of epitopes on tryptic fragments.","volume":"45","author":"NE Thompson","year":"1984","journal-title":"Infect Immun"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1128\/IAI.56.2.400-404.1988","article-title":"Cross-neutralization of staphylococcal and streptococcal pyrogenic toxins by monoclonal and polyclonal antibodies.","volume":"56","author":"GA Bohach","year":"1988","journal-title":"Infect Immun"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1128\/IAI.27.2.431-434.1980","article-title":"Isolation of specific and common antibodies to staphylococcal enterotoxins B, C1, and C2.","volume":"27","author":"AC Lee","year":"1980","journal-title":"Infect Immun"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1086\/314977","article-title":"Cross-reactive antibodies prevent the lethal effects of <italic>Staphylococcus aureus<\/italic> superantigens.","volume":"180","author":"S Bavari","year":"1999","journal-title":"J Infect Dis"},{"key":"ref11","first-page":"830","article-title":"Staphylococcal superantigens and the diseases they cause.","author":"T Uchiyama","year":"2006"},{"key":"ref12","first-page":"872","article-title":"Comparative three-dimensional structure of bacterial superantigenic toxins.","author":"T Baker","year":"2006"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1126\/science.2185544","article-title":"The staphylococcal enterotoxins and their relatives.","volume":"248","author":"P Marrack","year":"1990","journal-title":"Science"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.clinmicnews.2005.11.001","article-title":"Staphylococcal enterotoxins: a purging experience in review.","volume":"27","author":"BG Stiles","year":"2005","journal-title":"Clin Microbiol News"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10875-007-9072-4","article-title":"Structural and functional properties of antibodies to the superantigen TSST-1 and their relationship to menstrual toxic shock syndrome.","volume":"27","author":"R Kansal","year":"2007","journal-title":"J Clin Immunol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1128\/JCM.43.9.4628-4634.2005","article-title":"Prevalence of toxic shock syndrome toxin 1-producing <italic>Staphylococcus aureus<\/italic> and the presence of antibodies to this superantigen in menstruating women.","volume":"43","author":"J Parsonnet","year":"2005","journal-title":"J Clin Microbiol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10096-007-0405-2","article-title":"One in five mortality in non-menstrual toxic shock syndrome versus no mortality in menstrual cases in a balanced French series of 55 cases.","volume":"27","author":"E Descloux","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1086\/320170","article-title":"Recurrent nonmenstrual toxic shock syndrome: clinical manifestations, diagnosis, and treatment.","volume":"32","author":"MM Andrews","year":"2001","journal-title":"Clin Infect Dis"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1128\/IAI.56.1.135-141.1988","article-title":"Neutralization of toxic shock syndrome toxin-1 by monoclonal antibodies <italic>in vitro<\/italic> and <italic>in vivo<\/italic>.","volume":"56","author":"PF Bonventre","year":"1988","journal-title":"Infect Immun"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1128\/IAI.69.4.2031-2036.2001","article-title":"Mucosal vaccination with recombinantly-attenuated staphylococcal enterotoxin B and protection in a murine model.","volume":"69","author":"BG Stiles","year":"2001","journal-title":"Infect Immun"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0264-410X(98)00176-5","article-title":"Development of engineered vaccines effective against structurally related bacterial superantigens.","volume":"16","author":"RG Ulrich","year":"1998","journal-title":"Vaccine"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1521-6616(03)00066-4","article-title":"Generation of protective immunity by inactivated recombinant staphylococcal enterotoxin B vaccine in nonhuman primates and identification of correlates of immunity.","volume":"108","author":"JW Boles","year":"2003","journal-title":"Clin Immunol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1128\/IAI.63.4.1229-1234.1995","article-title":"Biological activity of toxic shock syndrome toxin 1 and a site-directed mutant, H135A, in a lipopolysaccharide-potentiated mouse lethality model.","volume":"63","author":"BG Stiles","year":"1995","journal-title":"Infect Immun"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1128\/IAI.67.3.1521-1525.1999","article-title":"Correlation of temperature and toxicity in murine studies of staphylococcal enterotoxins and toxic shock syndrome toxin 1.","volume":"67","author":"BG Stiles","year":"1999","journal-title":"Infect Immun"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0264-410X(96)00166-1","article-title":"Staphylococcal enterotoxin B mutants (N23K and F44S): biological effects and vaccine potential in a mouse model.","volume":"15","author":"MA Woody","year":"1997","journal-title":"Vaccine"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1128\/IAI.70.5.2278-2281.2002","article-title":"Protection against bacterial superantigen staphylococcal enterotoxin B by passive vaccination.","volume":"70","author":"RD LeClaire","year":"2002","journal-title":"Infect Immun"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1067\/mai.2001.117820","article-title":"Use of intravenous immunoglobulin in the treatment of staphylococcal and streptococcal toxic shock syndromes and related illnesses.","volume":"108","author":"PM Schlievert","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"ref28","article-title":"Immunotherapeutic strategies to combat staphylococcal infections.","author":"K Ohlsen","year":"2010","journal-title":"Int J Med Microbiol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s10156-007-0551-6","article-title":"Neutralization of staphylococcal exotoxins <italic>in vitro<\/italic> by human-origin intravenous immunoglobulin.","volume":"13","author":"C Yanagisawa","year":"2007","journal-title":"J Infect Chemother"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1086\/376630","article-title":"Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial.","volume":"37","author":"J Darenberg","year":"2003","journal-title":"Clin Infect Dis"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2332\/allergolint.O-06-462","article-title":"Gamma globulin inhibits superantigen-induced lymphocyte proliferation and cytokine production.","volume":"56","author":"K Kato","year":"2007","journal-title":"Allergol Int"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1086\/315198","article-title":"Lack of benefit of intravenous immune globulin in a murine model of group A streptococcal necrotizing fasciitis.","volume":"181","author":"R Patel","year":"2000","journal-title":"J Infect Dis"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jpeds.2007.04.060","article-title":"Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants.","volume":"151","author":"M Delonge","year":"2007","journal-title":"J Pediatr"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S0929-693X(07)80008-X","article-title":"Antibody for the prevention of neonatal nosocomial staphylococcal infection: a review of the literature.","volume":"14","author":"LE Weisman","year":"2007","journal-title":"Arch Pediatr"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1086\/381979","article-title":"Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome.","volume":"38","author":"J Darenberg","year":"2004","journal-title":"Clin Infect Dis"},{"key":"ref36","first-page":"197","article-title":"Intravenous immunoglobulin therapy in superantigen-mediated toxic shock syndrome.","author":"A Norrby-Teglund","year":"2007"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/157489109787236319","article-title":"Progress towards recombinant anti-infective antibodies.","volume":"4","author":"JC Pai","year":"2009","journal-title":"Recent Pat Antiinfect Drug Discov"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1128\/IAI.01731-05","article-title":"Isolation of human monoclonal antibody with strong neutralizing activity against diphtheria toxin.","volume":"74","author":"M Kakita","year":"2006","journal-title":"Infect Immun"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1006\/jmbi.1999.3444","article-title":"Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides.","volume":"296","author":"A Knappik","year":"2000","journal-title":"J Mol Biol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1128\/IAI.61.10.4254-4262.1993","article-title":"Characterization of novel type C staphylococcal enterotoxins: biological and evolutionary implications.","volume":"61","author":"JC Marr","year":"1993","journal-title":"Infect Immun"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1093\/clinids\/21.6.1469","article-title":"Clinical usefulness of intravenous human immunoglobulins in invasive group A streptococcal infections: case report and review.","volume":"21","author":"F Lamothe","year":"1995","journal-title":"Clin Infect Dis"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0002-9343(96)00304-X","article-title":"Adjunctive treatment of streptococcal toxic shock syndrome using intravenous immunoglobulin: case report and review.","volume":"102","author":"CM Perez","year":"1997","journal-title":"Amer J Med"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/INF.0b013e3180618c15","article-title":"Toxic shock syndrome in a neonate.","volume":"26","author":"C Powell","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1099\/jmm.0.2008\/002790-0","article-title":"Comparative prevalence of superantigenic toxin genes in meticillin-resistant and meticillin-susceptible <italic>Staphylococcus aureus<\/italic> isolates.","volume":"57","author":"DL Hu","year":"2008","journal-title":"J Med Microbiol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1128\/AAC.00096-06","article-title":"Phase II, randomized, double blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of <italic>Staphylococcus aureus<\/italic> bacteremia.","volume":"50","author":"JJ Weems","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1128\/AAC.50.2.511-518.2006","article-title":"Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both <italic>Staphylococcus aureus<\/italic> and <italic>Staphylococcus epidermidis<\/italic> infections <italic>in vivo<\/italic>.","volume":"50","author":"JH Vernachio","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.ijantimicag.2008.06.009","article-title":"Vaccination and passive immunisation against <italic>Staphylococcus aureus<\/italic>.","volume":"32","author":"AC Schaffer","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1128\/IAI.00617-08","article-title":"Proteomics-based identification of anchorless cell wall proteins as vaccine candidates against <italic>Staphylococcus aureus<\/italic>.","volume":"77","author":"E Glowalla","year":"2009","journal-title":"Infect Immun"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"11346","DOI":"10.1073\/pnas.172229899","article-title":"Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody.","volume":"99","author":"A Nowakowski","year":"2002","journal-title":"Proc Nat Acad Sci"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"466","DOI":"10.4049\/jimmunol.151.1.466","article-title":"Immunotherapy with human monoclonal antibodies. Fragment A specificity of polyclonal and monoclonal antibodies is crucial for full protection against tetanus toxin.","volume":"151","author":"AB Lang","year":"1993","journal-title":"J Immunol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1128\/IAI.01121-09","article-title":"Potent neutralization of SEB by synergistic action of chimeric antibodies.","volume":"78","author":"ME Tilahun","year":"2010","journal-title":"Infect Immun"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4049\/jimmunol.120.1.86","article-title":"On the cross-reactivity of staphylococcal enterotoxins A, B, and C.","volume":"120","author":"L Spero","year":"1978","journal-title":"J Immunol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF00198011","article-title":"Specificity, cross-reactivity and competition profile of monoclonal antibodies to staphylococcal enterotoxins B and C1 detected by indirect enzyme-linked immunosorbent assays.","volume":"178","author":"E Kienle","year":"1989","journal-title":"Med Microbiol Immunol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"669","DOI":"10.4049\/jimmunol.166.1.669","article-title":"egc, a highly prevalent operon of enterotoxin gene, forms a putative nursery of superantigens in <italic>Staphylococcus aureus<\/italic>.","volume":"166","author":"S Jarraud","year":"2001","journal-title":"J Immunol"},{"key":"ref55","first-page":"1","article-title":"Evolving superantigens of <italic>Staphylococcus aureus<\/italic>. FEMS Immunol.","volume":"27","author":"RG Ulrich","year":"2000","journal-title":"Med Microbiol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00431-006-0280-3","article-title":"A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease.","volume":"166","author":"K Sakata","year":"2007","journal-title":"Eur J Pediatr"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/j.1468-1331.2007.01929.x","article-title":"Influence of impaired T- and B-cell compartments on efficacy of IVIg in dysimmune neuropathies.","volume":"14","author":"S Mata","year":"2007","journal-title":"Eur J Neurol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.amjopharm.2007.03.001","article-title":"Use of intravenous immunoglobulin for the treatment of severe <italic>Clostridium difficile<\/italic> colitis.","volume":"5","author":"A Hassoun","year":"2007","journal-title":"Am J Geriatr Pharmacother"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1016\/j.clinph.2007.05.001","article-title":"Long-term effects of intravenous immunoglobulin in CIDP.","volume":"118","author":"S Vucic","year":"2007","journal-title":"Clin Neurophysiol"},{"key":"ref60","first-page":"S28","article-title":"Intravenous immunoglobulins in polyarteritis nodosa restricted to the limbs: case reports and review of the literature.","volume":"25","author":"A Balbir-Gurman","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"ref61","first-page":"103","article-title":"Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab.","volume":"317","author":"H Wu","year":"2008","journal-title":"Curr Top Microbiol Immunol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/ajh.21008","article-title":"Successfultreatment of cytomegalovirus-associated hemophagocytic syndrome by intravenous immunoglobulins.","volume":"83","author":"A Hot","year":"2008","journal-title":"Am J Hematol"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1172\/JCI116240","article-title":"Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens.","volume":"91","author":"S Takei","year":"1993","journal-title":"J Clin Invest"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nsb0795-554","article-title":"Staphylococcal enterotoxins A and B share a common structural motif for binding class II major histocompatibility complex molecules.","volume":"2","author":"RG Ulrich","year":"1995","journal-title":"Nat Struct Biol"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1128\/IAI.63.2.423-429.1995","article-title":"Staphylococcal enterotoxin A and toxic shock syndrome toxin compete with CD4 for human major histocompatibility complex class II binding.","volume":"63","author":"S Bavari","year":"1995","journal-title":"Infect Immun"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0013253","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T19:48:25Z","timestamp":1685821705000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0013253"}},"subtitle":[],"editor":[{"given":"Malcolm James","family":"Horsburgh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,10,11]]},"references-count":65,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2010,10,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0013253","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,11]]}}}